title: Effect of high-dose aspirin on Helicobacter pylori eradication.
abstract: We conducted a pilot study aimed at comparing the efficacy of the standard OAC (omeprazole-amoxicillin-clarithromycin) regimen with a combination of the OAC regimen and aspirin (OACA). Follow-up endoscopic findings showed that the previous ulcers were completely healed in all subjects. The eradication rates (per protocol) were 80.3% (49/61) in the OAC group and 86.7% (52/60) in the OACA group. The eradication rate was not significantly different between the two groups. The most common adverse event was a bad taste, and the overall adverse events were similar in the two groups. The combination of the OAC regimen and aspirin was not significantly superior to the standard OAC regimen, but it was well tolerated in a group of patients with peptic ulcer disease. Its potential for clinical use to augment the efficacy of H. pylori eradication may warrant further investigation.
authors.affiliation: Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul, Korea.
authors.forename: Seung Ha
authors.initials: SH
authors.lastname: Park
authors.forename: Dong Il
authors.initials: DI
authors.lastname: Park
authors.forename: Sang Hoon
authors.initials: SH
authors.lastname: Kim
authors.forename: Hong Joo
authors.initials: HJ
authors.lastname: Kim
authors.forename: Yong Kyun
authors.initials: YK
authors.lastname: Cho
authors.forename: In Kyung
authors.initials: IK
authors.lastname: Sung
authors.forename: Chong Il
authors.initials: CI
authors.lastname: Sohn
authors.forename: Woo Kyu
authors.initials: WK
authors.lastname: Jeon
authors.forename: Byung Ik
authors.initials: BI
authors.lastname: Kim
authors.forename: Dong Keuk
authors.initials: DK
authors.lastname: Keum
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005756:Gastritis / Q000382:microbiology / Q000473:pathology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects; D010437:Peptic Ulcer / Q000382:microbiology / Q000473:pathology; D010865:Pilot Projects
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole; D001241:Aspirin